Xenome Ltd’s Hopes for Painkiller Hit Trouble, Considers Partners for New Strategy

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DRUG developer Xenome, once heralded as a potential star for Queensland's biotechnology industry, has suffered a major setback. Plans to develop Xenome's molecule, derived from shellfish venom, to soothe acute post-surgery pain, have been shipwrecked. It failed to meet safety targets set by US regulators, a $20 million blow for Xenome.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC